首页> 美国卫生研究院文献>Indian Heart Journal >Nanomedicine in coronary artery disease
【2h】

Nanomedicine in coronary artery disease

机译:纳米药物在冠心病中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nanomedicine is one of the most promising therapeutic modalities researchers are working on. It involves development of drugs and devices that work at the nanoscale (10–9 m). Coronary artery disease (CAD) is responsible for more than a third of all deaths in age group >35 years. With such a huge burden of mortality, CAD is one of the diseases where nanomedicine is being employed for preventive and therapeutic interventions. Nanomedicine can effectively deliver focused drug payload at sites of local plaque formation. Non-invasive strategies include thwarting angiogenesis, intra-arterial thrombosis and local inflammation. Invasive strategies following percutaneous coronary intervention (PCI) include anti-restenosis and healing enhancement. However, before practical application becomes widespread, many challenges need to be dealt with. These include manufacturing at the nanoscale, direct nanomaterial cellular toxicity and visualization.
机译:纳米医学是研究人员正在研究的最有前途的治疗方法之一。它涉及开发可在纳米级(10–9 m)工作的药物和设备。在35岁以上的年龄组中,冠状动脉疾病(CAD)占所有死亡人数的三分之一以上。伴随着如此巨大的死亡负担,CAD是其中采用纳米医学进行预防和治疗干预的疾病之一。纳米医学可以在局部斑块形成部位有效地提供集中的药物有效载荷。非侵入性策略包括阻止血管生成,动脉内血栓形成和局部炎症。经皮冠状动脉介入治疗(PCI)后的浸润策略包括抗再狭窄和促进愈合。但是,在实际应用变得广泛之前,需要应对许多挑战。这些包括纳米级制造,直接的纳米材料细胞毒性和可视化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号